메뉴 건너뛰기




Volumn 275, Issue 1, 2014, Pages 1-11

Advantages and limitations of the new anticoagulants

Author keywords

Adherence; Bleeding; Factor Xa inhibitor; Monitoring; Thrombin inhibitor

Indexed keywords

AMIODARONE; APIXABAN; CLARITHROMYCIN; DABIGATRAN; EDOXABAN; EFEGATRAN; HIRUDIN; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; MELAGATRAN; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; VERAPAMIL; WARFARIN; XIMELAGATRAN;

EID: 84890170924     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12138     Document Type: Review
Times cited : (80)

References (61)
  • 1
    • 0033527355 scopus 로고    scopus 로고
    • Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis
    • Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
    • (1999) Ann Intern Med , vol.131 , pp. 492-501
    • Hart, R.G.1    Benavente, O.2    McBride, R.3    Pearce, L.A.4
  • 2
    • 0033602514 scopus 로고    scopus 로고
    • A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
    • Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
    • (1999) N Engl J Med , vol.340 , pp. 901-907
    • Kearon, C.1    Gent, M.2    Hirsh, J.3
  • 3
    • 8044235654 scopus 로고    scopus 로고
    • The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group
    • Schulman S, Granqvist S, Holmström M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336: 393-8.
    • (1997) N Engl J Med , vol.336 , pp. 393-398
    • Schulman, S.1    Granqvist, S.2    Holmström, M.3
  • 4
    • 0344861847 scopus 로고    scopus 로고
    • Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
    • Go AS, Hylek EM, Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685-92.
    • (2003) JAMA , vol.290 , pp. 2685-2692
    • Go, A.S.1    Hylek, E.M.2    Chang, Y.3
  • 5
    • 84863301351 scopus 로고    scopus 로고
    • Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal
    • Dowlatshahi D, Butcher KS, Asdaghi N et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012; 43: 1812-7.
    • (2012) Stroke , vol.43 , pp. 1812-1817
    • Dowlatshahi, D.1    Butcher, K.S.2    Asdaghi, N.3
  • 6
    • 65549143562 scopus 로고    scopus 로고
    • The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage
    • Flaherty ML, Adeoye O, Sekar P et al. The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage. Stroke 2009; 40: 1738-42.
    • (2009) Stroke , vol.40 , pp. 1738-1742
    • Flaherty, M.L.1    Adeoye, O.2    Sekar, P.3
  • 7
    • 0028833019 scopus 로고
    • Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly
    • McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155: 277-81.
    • (1995) Arch Intern Med , vol.155 , pp. 277-281
    • McCrory, D.C.1    Matchar, D.B.2    Samsa, G.3    Sanders, L.L.4    Pritchett, E.L.5
  • 9
    • 0035851288 scopus 로고    scopus 로고
    • Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting
    • McCormick D, Gurwitz JH, Goldberg RJ et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001; 161: 2458-63.
    • (2001) Arch Intern Med , vol.161 , pp. 2458-2463
    • McCormick, D.1    Gurwitz, J.H.2    Goldberg, R.J.3
  • 10
    • 84890173866 scopus 로고
    • The action of hirudin upon thrombin
    • Barratt JO. The action of hirudin upon thrombin. J Physiol 1927; 64: 47-53.
    • (1927) J Physiol , vol.64 , pp. 47-53
    • Barratt, J.O.1
  • 11
    • 45949098057 scopus 로고    scopus 로고
    • Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    • Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 257S-98S.
    • (2008) Chest , vol.133
    • Schulman, S.1    Beyth, R.J.2    Kearon, C.3    Levine, M.N.4
  • 12
    • 0033179314 scopus 로고    scopus 로고
    • Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina
    • Klootwijk P, Lenderink T, Meij S et al. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J 1999; 20: 1101-11.
    • (1999) Eur Heart J , vol.20 , pp. 1101-1111
    • Klootwijk, P.1    Lenderink, T.2    Meij, S.3
  • 13
    • 0026465007 scopus 로고
    • Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics
    • Brandstetter H, Turk D, Hoeffken HW et al. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. J Mol Biol 1992; 226: 1085-99.
    • (1992) J Mol Biol , vol.226 , pp. 1085-1099
    • Brandstetter, H.1    Turk, D.2    Hoeffken, H.W.3
  • 14
    • 84890248651 scopus 로고    scopus 로고
    • Trypsin-like protease-inhibiting peptide derivatives, their synthesis and therapeutic use. Patent application WO9429336-A1. CA122-285553/23.
    • Antonsson KT, Bylund R, Gustafsson ND, Nilsson IO. Trypsin-like protease-inhibiting peptide derivatives, their synthesis and therapeutic use. Patent application WO9429336-A1. CA122-285553/23.
    • Antonsson, K.T.1    Bylund, R.2    Gustafsson, N.D.3    Nilsson, I.O.4
  • 15
    • 0742284689 scopus 로고    scopus 로고
    • The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study
    • Eriksson BI, Agnelli G, Cohen AT et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490-6.
    • (2003) J Thromb Haemost , vol.1 , pp. 2490-2496
    • Eriksson, B.I.1    Agnelli, G.2    Cohen, A.T.3
  • 16
    • 0037329702 scopus 로고    scopus 로고
    • Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study
    • Eriksson BI, Agnelli G, Cohen AT et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb Haemost 2003; 89: 288-96.
    • (2003) Thromb Haemost , vol.89 , pp. 288-296
    • Eriksson, B.I.1    Agnelli, G.2    Cohen, A.T.3
  • 17
    • 0345414673 scopus 로고    scopus 로고
    • Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
    • Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-8.
    • (2003) Lancet , vol.362 , pp. 1691-1698
    • Olsson, S.B.1
  • 18
    • 13444309949 scopus 로고    scopus 로고
    • Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial
    • Albers GW, Diener HC, Frison L et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-8.
    • (2005) JAMA , vol.293 , pp. 690-698
    • Albers, G.W.1    Diener, H.C.2    Frison, L.3
  • 19
    • 13444278653 scopus 로고    scopus 로고
    • Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial
    • Fiessinger JN, Huisman MV, Davidson BL et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 681-9.
    • (2005) JAMA , vol.293 , pp. 681-689
    • Fiessinger, J.N.1    Huisman, M.V.2    Davidson, B.L.3
  • 20
    • 0142182558 scopus 로고    scopus 로고
    • Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran
    • Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713-21.
    • (2003) N Engl J Med , vol.349 , pp. 1713-1721
    • Schulman, S.1    Wahlander, K.2    Lundstrom, T.3    Clason, S.B.4    Eriksson, H.5
  • 22
    • 45949103309 scopus 로고    scopus 로고
    • Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    • Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-98S.
    • (2008) Chest , vol.133
    • Ansell, J.1    Hirsh, J.2    Hylek, E.3    Jacobson, A.4    Crowther, M.5    Palareti, G.6
  • 23
    • 84859156077 scopus 로고    scopus 로고
    • Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement
    • Dahl OE, Kurth AA, Rosencher N, Noack H, Clemens A, Eriksson BI. Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement. Int Orthop 2012; 36: 741-8.
    • (2012) Int Orthop , vol.36 , pp. 741-748
    • Dahl, O.E.1    Kurth, A.A.2    Rosencher, N.3    Noack, H.4    Clemens, A.5    Eriksson, B.I.6
  • 24
    • 84861616750 scopus 로고    scopus 로고
    • Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial
    • Hart RG, Diener HC, Yang S et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-7.
    • (2012) Stroke , vol.43 , pp. 1511-1517
    • Hart, R.G.1    Diener, H.C.2    Yang, S.3
  • 25
    • 0035854054 scopus 로고    scopus 로고
    • Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation
    • Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
    • (2001) JAMA , vol.285 , pp. 2864-2870
    • Gage, B.F.1    Waterman, A.D.2    Shannon, W.3    Boechler, M.4    Rich, M.W.5    Radford, M.J.6
  • 26
    • 70349306707 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation
    • Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
    • (2009) N Engl J Med , vol.361 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 27
    • 80052825103 scopus 로고    scopus 로고
    • Apixaban versus warfarin in patients with atrial fibrillation
    • Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
    • (2011) N Engl J Med , vol.365 , pp. 981-992
    • Granger, C.B.1    Alexander, J.H.2    McMurray, J.J.3
  • 28
    • 80052592404 scopus 로고    scopus 로고
    • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    • Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
    • (2011) N Engl J Med , vol.365 , pp. 883-891
    • Patel, M.R.1    Mahaffey, K.W.2    Garg, J.3
  • 29
    • 84859385808 scopus 로고    scopus 로고
    • Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
    • Buller HR, Prins MH, Lensing AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97.
    • (2012) N Engl J Med , vol.366 , pp. 1287-1297
    • Buller, H.R.1    Prins, M.H.2    Lensing, A.W.3
  • 30
    • 71849117615 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    • Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.
    • (2009) N Engl J Med , vol.361 , pp. 2342-2352
    • Schulman, S.1    Kearon, C.2    Kakkar, A.K.3
  • 31
    • 0029741822 scopus 로고    scopus 로고
    • An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation
    • Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-6.
    • (1996) N Engl J Med , vol.335 , pp. 540-546
    • Hylek, E.M.1    Skates, S.J.2    Sheehan, M.A.3    Singer, D.E.4
  • 32
    • 0026569416 scopus 로고
    • Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
    • Prandoni P, Lensing AW, Buller HR et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-5.
    • (1992) Lancet , vol.339 , pp. 441-445
    • Prandoni, P.1    Lensing, A.W.2    Buller, H.R.3
  • 33
    • 77953168824 scopus 로고    scopus 로고
    • Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    • van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-27.
    • (2010) Thromb Haemost , vol.103 , pp. 1116-1127
    • van Ryn, J.1    Stangier, J.2    Haertter, S.3
  • 34
    • 84862146631 scopus 로고    scopus 로고
    • Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban
    • Harenberg J, Marx S, Weiss C, Kramer R, Samama M, Schulman S. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 2012; 10: 1433-6.
    • (2012) J Thromb Haemost , vol.10 , pp. 1433-1436
    • Harenberg, J.1    Marx, S.2    Weiss, C.3    Kramer, R.4    Samama, M.5    Schulman, S.6
  • 35
    • 77953787643 scopus 로고    scopus 로고
    • Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers
    • Ogata K, Mendell-Harary J, Tachibana M et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50: 743-53.
    • (2010) J Clin Pharmacol , vol.50 , pp. 743-753
    • Ogata, K.1    Mendell-Harary, J.2    Tachibana, M.3
  • 37
    • 84857853180 scopus 로고    scopus 로고
    • Bleeding risk with dabigatran in the frail elderly
    • Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 864-6.
    • (2012) N Engl J Med , vol.366 , pp. 864-866
    • Harper, P.1    Young, L.2    Merriman, E.3
  • 38
    • 84863660210 scopus 로고    scopus 로고
    • Dabigatran: uncharted waters and potential harms
    • Radecki RP. Dabigatran: uncharted waters and potential harms. Ann Intern Med 2012; 157: 66-8.
    • (2012) Ann Intern Med , vol.157 , pp. 66-68
    • Radecki, R.P.1
  • 39
    • 84890191290 scopus 로고    scopus 로고
    • Management and outcomes of major bleeding on dabigatran or warfarin
    • Epub ahead of print].
    • Majeed A, Hwang H-G, Brueckmann M et al. Management and outcomes of major bleeding on dabigatran or warfarin. Circulation 2013; [Epub ahead of print].
    • (2013) Circulation
    • Majeed, A.1    Hwang, H.-G.2    Brueckmann, M.3
  • 40
    • 84863989146 scopus 로고    scopus 로고
    • Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial
    • Healey JS, Eikelboom J, Douketis J et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 2012; 126: 343-8.
    • (2012) Circulation , vol.126 , pp. 343-348
    • Healey, J.S.1    Eikelboom, J.2    Douketis, J.3
  • 41
    • 84875780959 scopus 로고    scopus 로고
    • Dabigatran and postmarketing reports of bleeding
    • Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272-4.
    • (2013) N Engl J Med , vol.368 , pp. 1272-1274
    • Southworth, M.R.1    Reichman, M.E.2    Unger, E.F.3
  • 42
    • 84878292470 scopus 로고    scopus 로고
    • Efficacy and safety of dabigatran etexilate and warfarin in 'real world' patients with atrial fibrillation: a prospective nationwide cohort study
    • Larsen TB, Rasmussen LH, Skjoth F et al. Efficacy and safety of dabigatran etexilate and warfarin in 'real world' patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-73.
    • (2013) J Am Coll Cardiol , vol.61 , pp. 2264-2273
    • Larsen, T.B.1    Rasmussen, L.H.2    Skjoth, F.3
  • 43
    • 84890158908 scopus 로고    scopus 로고
    • Dabigatran versus warfarin among patients with atrial fibrillation: real-world post-market results
    • Abstract).
    • Thelus R, Villiness TC, Coster TS. Dabigatran versus warfarin among patients with atrial fibrillation: real-world post-market results. Circulation 2012; 126: A14877 (Abstract).
    • (2012) Circulation , vol.126
    • Thelus, R.1    Villiness, T.C.2    Coster, T.S.3
  • 44
    • 84893179904 scopus 로고    scopus 로고
    • Mortality in vitamin K antagonists-related intracerebral bleeding treated with plasma or prothrombin complex concentrate
    • Abstr PB 145-Abstr PB 144
    • Majeed A, Meijer K, Larrazabal R et al. Mortality in vitamin K antagonists-related intracerebral bleeding treated with plasma or prothrombin complex concentrate. J Thromb Haemost 2013; 11: Abstr PB 1.45-4.
    • (2013) J Thromb Haemost , vol.11
    • Majeed, A.1    Meijer, K.2    Larrazabal, R.3
  • 45
    • 84879548455 scopus 로고    scopus 로고
    • A specific antidote for dabigatran: functional and structural characterization
    • Schiele F, van Ryn J, Canada K et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-62.
    • (2013) Blood , vol.121 , pp. 3554-3562
    • Schiele, F.1    van Ryn, J.2    Canada, K.3
  • 46
    • 84878460192 scopus 로고    scopus 로고
    • A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
    • Lu G, DeGuzman FR, Hollenbach SJ et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-51.
    • (2013) Nat Med , vol.19 , pp. 446-451
    • Lu, G.1    DeGuzman, F.R.2    Hollenbach, S.J.3
  • 47
    • 33646449376 scopus 로고    scopus 로고
    • Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency
    • Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-84.
    • (2006) Ann Intern Med , vol.144 , pp. 673-684
    • Lim, W.1    Dentali, F.2    Eikelboom, J.W.3    Crowther, M.A.4
  • 48
    • 1642326695 scopus 로고    scopus 로고
    • Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin
    • Thorevska N, Amoateng-Adjepong Y, Sabahi R et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125: 856-63.
    • (2004) Chest , vol.125 , pp. 856-863
    • Thorevska, N.1    Amoateng-Adjepong, Y.2    Sabahi, R.3
  • 49
    • 0016916438 scopus 로고
    • Prediction of creatinine clearance from serum creatinine
    • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
    • (1976) Nephron , vol.16 , pp. 31-41
    • Cockcroft, D.W.1    Gault, M.H.2
  • 50
    • 84877692612 scopus 로고    scopus 로고
    • Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly
    • Hellden A, Odar-Cederlof I, Nilsson G et al. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open 2013; 3: e002686.
    • (2013) BMJ Open , vol.3
    • Hellden, A.1    Odar-Cederlof, I.2    Nilsson, G.3
  • 51
    • 0036162863 scopus 로고    scopus 로고
    • Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes
    • Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002; 95: 68-71.
    • (2002) South Med J , vol.95 , pp. 68-71
    • Dezii, C.M.1    Kawabata, H.2    Tran, M.3
  • 52
    • 84890142021 scopus 로고    scopus 로고
    • Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and race
    • Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CE. Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and race. Diabetes Educ 1999; 5: 7-8.
    • (1999) Diabetes Educ , vol.5 , pp. 7-8
    • Sclar, D.A.1    Robison, L.M.2    Skaer, T.L.3    Dickson, W.M.4    Kozma, C.M.5    Reeder, C.E.6
  • 53
    • 13944282109 scopus 로고    scopus 로고
    • Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure
    • Tu W, Morris AB, Li J et al. Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin Pharmacol Ther 2005; 77: 189-201.
    • (2005) Clin Pharmacol Ther , vol.77 , pp. 189-201
    • Tu, W.1    Morris, A.B.2    Li, J.3
  • 54
    • 84880430786 scopus 로고    scopus 로고
    • Adherence to anticoagulant treatment with dabigatran in a real-world setting
    • Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013; 11: 1295-9.
    • (2013) J Thromb Haemost , vol.11 , pp. 1295-1299
    • Schulman, S.1    Shortt, B.2    Robinson, M.3    Eikelboom, J.W.4
  • 55
    • 45949104683 scopus 로고    scopus 로고
    • Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    • Salem DN, O'Gara PT, Madias C, Pauker SG. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 593S-629S.
    • (2008) Chest , vol.133
    • Salem, D.N.1    O'Gara, P.T.2    Madias, C.3    Pauker, S.G.4
  • 56
    • 84857021520 scopus 로고    scopus 로고
    • Dabigatran association with higher risk of acute coronary events: meta-analysis of non-inferiority randomized controlled trials
    • Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of non-inferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
    • (2012) Arch Intern Med , vol.172 , pp. 397-402
    • Uchino, K.1    Hernandez, A.V.2
  • 58
    • 84874003257 scopus 로고    scopus 로고
    • Extended use of dabigatran, warfarin or placebo in venous thromboembolism
    • Schulman S, Kearon C, Kakkar AK et al. Extended use of dabigatran, warfarin or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-18.
    • (2013) N Engl J Med , vol.368 , pp. 709-718
    • Schulman, S.1    Kearon, C.2    Kakkar, A.K.3
  • 59
    • 84862530985 scopus 로고    scopus 로고
    • A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II)
    • Abstr 205
    • Schulman S, Kakkar AK, Schellong S et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood 2011; 118: Abstr 205.
    • (2011) Blood , vol.118
    • Schulman, S.1    Kakkar, A.K.2    Schellong, S.3
  • 60
    • 78650619315 scopus 로고    scopus 로고
    • Oral rivaroxaban for symptomatic venous thromboembolism
    • Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.
    • (2010) N Engl J Med , vol.363 , pp. 2499-2510
    • Bauersachs, R.1    Berkowitz, S.D.2    Brenner, B.3
  • 61
    • 84880327613 scopus 로고    scopus 로고
    • Oral apixaban for the treatment of acute venous thromboembolism
    • Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
    • (2013) N Engl J Med , vol.369 , pp. 799-808
    • Agnelli, G.1    Buller, H.R.2    Cohen, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.